Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Ljubljana Stock Exchange  >  Krka, d. d.    KRKG   SI0031102120


End-of-day quote. End-of-day quote Ljubljana Stock Exchange - 01/15
96.2 EUR   -0.82%
2020KRKA D D : Reports Business Results for the First Nine Months Ended 30 September 2020
2020KRKA, D. D. : quaterly earnings release
2020KRKA, D. D. : Ex-dividend day for final dividend
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Krka d d Novo Mesto : Live longer. Live better. Can we?

09/06/2019 | 08:52am EST

6. 9. 2019

The answer is Yes. But we need to know how. We are often not aware that we can create the future. Not in all aspects, but in many. Our personal contribution means a lot. Using the knowledge in the right way can change our lives. Knowledge combined with global action can change the world.


How to change the outcomes of cardiovascular disease that has been the leading global cause of death for the past decades was the main issue of Krka's international symposium The Power of Synergy, organized in Paris on 31 August, parallel to the ESC Congress 2019. More than 260 symposium guests from 17 countries were absorbed in listening to the expertise of one of the world's most distinguished cardiologists, Prof. Salim Yusuf from Canada, and one of the most renowned European cardiology experts, Prof. Michal Vrablík from the Czech Republic.

The eminent experts emphasised that cardiovascular disease still represents 1/3 of all deaths worldwide (over 15 million deaths1); more than all infectious, maternal, neonatal and nutritional disorders combined, and double the number of deaths caused by cancers.

Hypertension and hyperlipidemia remain the leading risk factors for cardiovascular disease. The good news is: They can be controlled. The bad news is: They are not controlled well.

Everything is clear in theory. But what is causing the gap between theory and practice?

The symposium guests, mainly cardiology specialists, shared the opinion that addressing the major two CVD risk factors is an opportunity, which should be used better. The tools are available which can help reaching the common goal: to live longer and better. Among them also Krka's single-pill combinations of rosuvastatin and valsartan and the recently launched rosuvastatin, perindopril and indapamide, which enable treatment of hypertension and hyperlipidemia with just one pill daily.

ESC - European Society of Cardiology
CVD - cardiovascular disease

1. Nichols M, Townsend N, Scarborough P et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014; 35: 2950-59.


KRKA dd published this content on 06 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 September 2019 12:51:02 UTC

© Publicnow 2019
All news about KRKA, D. D.
2020KRKA D D : Reports Business Results for the First Nine Months Ended 30 September..
2020KRKA, D. D. : quaterly earnings release
2020KRKA, D. D. : Ex-dividend day for final dividend
2020KRKA D D : Reports First Quarter 2020 Business Results
2020KRKA, D. D. : quaterly earnings release
2020KRKA D D : Proposed dividend for Krka shareholders 32.8% higher than last year
2020KRKA D D : Presents the 2019 Unaudited Performance Results
2020KRKA D D NOVO MESTO : Estimation of Krka Business Performance in 2019
2019KRKA D D NOVO MESTO : receives two prestigious awards by the Ljubljana Stock Exc..
2019KRKA D D NOVO MESTO : Presents January–September 2019 Operating Results
More news
Sales 2020 1 563 M 1 885 M 1 885 M
Net income 2020 255 M 307 M 307 M
Net cash 2020 309 M 373 M 373 M
P/E ratio 2020 12,4x
Yield 2020 4,50%
Capitalization 3 012 M 3 642 M 3 632 M
EV / Sales 2020 1,73x
EV / Sales 2021 1,67x
Nbr of Employees 11 503
Free-Float 67,3%
Chart KRKA, D. D.
Duration : Period :
Krka, d. d. Technical Analysis Chart | KRKG | SI0031102120 | MarketScreener
Technical analysis trends KRKA, D. D.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 92,50 €
Last Close Price 96,20 €
Spread / Highest target 9,67%
Spread / Average Target -3,85%
Spread / Lowest Target -29,3%
EPS Revisions
Managers and Directors
Jože Colaric President-Management Board & CEO
Jože Mermal Chairman-Supervisory Board
Brane Kastelec Finance Director
Aleš Rotar Director-Pharmaceutical Research & Development
Miran Kapš Director-Information Technology
Sector and Competitors